Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $35.36 USD
Change Today -0.40 / -1.12%
Volume 403.5K
MYGN On Other Exchanges
As of 8:10 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYGN) Key Developments

Myriad Genetics Inc. Announces Prolaris Test Biopsy Results from EMPATHY-P Study at European Association of Urology Annual Meeting

Myriad Genetics Inc. announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods (D'Amico/AUA risk stratification), which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology. Specifically, EMPATHY-P demonstrated that the Prolaris test score found 22% of the European patients had less aggressive prostate cancer and 20% had more aggressive prostate cancer compared to standard clinical pathology measurements. Prolaris is a novel 46-gene RNA-expression test that directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. Prolaris provides a quantitative measure of the RNA expression levels of genes involved in the progression of tumor growth. Low gene expression is associated with a low risk of disease progression in men who may be candidates for active surveillance and high gene expression is associated with a higher risk of disease progression in patients who may benefit from additional therapy.

Myriad Genetics Seeks Acquisitions

Mark Capone, President, Chief Executive Officer & Director of Myriad Genetics Inc. (NasdaqGS:MYGN) said, "I think as we reflect on that, I would love to find other opportunities like Crescendo that are generating this level of revenue that have line of sight to being accretive in the not too distant future in a very large market that's $1.5 billion market that can be served by 40 sales people. I would love to have other acquisition opportunities in that category. Unfortunately, there are not that many quality opportunities out there in this space and that's why you haven't seen us be more acquisitive, but certainly, we would take that opportunity anytime we could get it to find an asset like that."

Myriad Genetics Launches New Blood Survey Tool

Myriad Genetics (MYGN) reported on the launch of immunoassay services based on its sensitive, single-molecule array diagnostic platform. MYGN said the platform enables the accurate measurement of protein biomarkers in blood that were previously difficult or even impossible to detect.

Myriad Genetics, Inc. Publishes myPath Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics Inc. announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90% diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States. The published study describes the discovery, verification and clinical validation of the myPath Melanoma test, which was designed to differentiate benign moles from malignant melanoma. The myPath Melanoma test was developed using a verification cohort of 464 patient samples and was validated in a separate independent study with 437 patient samples from academic medical centers in the United States. In both the verification and validation studies, the myPath Melanoma test demonstrated a greater than 90% diagnostic accuracy, making it the most accurate molecular diagnostic test developed to date for melanoma. These clinical findings validate the performance, objectivity and reliability of the myPath Melanoma test for clinical use to improve the diagnosis of melanoma. About Myriad myPath Melanoma Testing: Myriad myPath Melanoma is a clinically validated gene expression test designed to differentiate malignant melanoma from benign nevi across all major melanoma subtypes.

Myriad Genetics Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 11:15 AM

Myriad Genetics Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 11:15 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Mark Christopher Capone, President of Myriad Genetic Laboratories.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $35.36 USD -0.40

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $29.63 USD +0.53
Alliance HealthCare Services Inc $22.15 USD +1.30
Bio-Reference Laboratories Inc $35.10 USD -0.07
Genomic Health Inc $30.89 USD +0.68
RadNet Inc $8.48 USD +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation MYGN Industry Range
Price/Earnings 24.7x
Price/Sales 3.6x
Price/Book 3.7x
Price/Cash Flow 23.0x
TEV/Sales 3.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at